Two proteins previously known as Na ϩ -dependent phosphate transporters have been identified recently as vesicular glutamate transporters (VGLUT1 and VGLUT2). Together, VGLUT1 and VGLUT2 are operating at most central glutamatergic synapses. In this study, we characterized a third vesicular glutamate transporter (VGLUT3), highly homologous to VGLUT1 and VGLUT2. Vesicles isolated from endocrine cells expressing recombinant VGLUT3 accumulated L-glutamate with bioenergetic and pharmacological characteristics similar, but not identical, to those displayed by the type-1 and type-2 isoforms. Interestingly, the distribution of VGLUT3 mRNA was restricted to a small number of neurons scattered in the striatum, hippocampus, cerebral cortex, and raphe nuclei, in contrast to VGLUT1 and VGLUT2 transcripts, which are massively expressed in cortical and deep structures of the brain, respectively. At the ultrastructural level, VGLUT3 immunoreactivity was concentrated over synaptic vesicle clusters present in nerve endings forming asymmetrical as well as symmetrical synapses. Finally, VGLUT3-positive neurons of the striatum and raphe nuclei were shown to coexpress acetylcholine and serotonin transporters, respectively. Our study reveals a novel class of glutamatergic nerve terminals and suggests that cholinergic striatal interneurons and serotoninergic neurons from the brainstem may store and release glutamate.
Two proteins previously known as Na ϩ -dependent phosphate transporters have been identified recently as vesicular glutamate transporters (VGLUT1 and VGLUT2). Together, VGLUT1 and VGLUT2 are operating at most central glutamatergic synapses. In this study, we characterized a third vesicular glutamate transporter (VGLUT3), highly homologous to VGLUT1 and VGLUT2. Vesicles isolated from endocrine cells expressing recombinant VGLUT3 accumulated L-glutamate with bioenergetic and pharmacological characteristics similar, but not identical, to those displayed by the type-1 and type-2 isoforms. Interestingly, the distribution of VGLUT3 mRNA was restricted to a small number of neurons scattered in the striatum, hippocampus, cerebral cortex, and raphe nuclei, in contrast to VGLUT1 and VGLUT2 transcripts, which are massively expressed in cortical and deep structures of the brain, respectively. At the ultrastructural level, VGLUT3 immunoreactivity was concentrated over synaptic vesicle clusters present in nerve endings forming asymmetrical as well as symmetrical synapses. Finally, VGLUT3-positive neurons of the striatum and raphe nuclei were shown to coexpress acetylcholine and serotonin transporters, respectively. Our study reveals a novel class of glutamatergic nerve terminals and suggests that cholinergic striatal interneurons and serotoninergic neurons from the brainstem may store and release glutamate.
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Glutamate, a neurotransmitter used by a majority of excitatory connections in the mammalian brain, has to be loaded into synaptic vesicles by proton-dependent transporters before its exocytotic release (Ozkan and Ueda, 1998; Reimer et al., 1998; Erickson and Varoqui, 2000; Gasnier, 2000) . Brain-specific Na ϩ -dependent inorganic phosphate transporter (Ni et al., 1994) and differentiation-associated Na ϩ -dependent inorganic phosphate transporter (Aihara et al., 2000) , two members of the Na ϩ -dependent inorganic phosphate transporter family, are now unambiguously established as two vesicular glutamate transporters (VGLUT1 and VGLUT2) by an array of biochemical, anatomical, electrophysiological, and genetic evidence (Dent et al., 1997; Lee et al., 1999; Bellocchio et al., 2000; Takamori et al., 2000 Takamori et al., , 2001 Bai et al., 2001; Fremeau et al., 2001; Herzog et al., 2001) . Both transporters are abundantly expressed in the brain (Ni et al., 1995; Hisano et al., 1997) . VGLUT1 is massively present in excitatory neurons from the cerebral and cerebellar cortices, as well as the hippocampus, whereas most glutamatergic neurons from the diencephalon and rhombencephalon preferentially use VGLUT2 (Fremeau et al., 2001; Herzog et al., 2001; Varoqui et al., 2002) . At the subcellular level, VGLUT1 and VGLUT2 are found in synaptic vesicles located in terminals forming asymmetrical contacts (Bellocchio et al., 1998; Fremeau et al., 2001; Fujiyama et al., 2001; Hayashi et al., 2001; Sakata-Haga et al., 2001; Takamori et al., 2001; Varoqui et al., 2002) , the hallmark of glutamatergic terminals (Shepherd, 1998) . Together, VGLUT1 and VGLUT2, with their complementary distributions, seem to account for most of the known glutamatergic neurons of the CNS (Fremeau et al., 2001; Varoqui et al., 2002) .
We now report the isolation of VGLUT3, an unforeseen third vesicular glutamate transporter. Although structurally and functionally closely related to the widely expressed VGLUT1 and VGLUT2, this novel transporter exhibits several unique features. In particular, it is found in all cholinergic interneurons of the striatum, as well as in serotoninergic neurons from the raphe nuclei.
MATERIALS AND METHODS
cDNA cloning and e xpression in BON cells. VGLUT3 f ull-length clones were obtained by screening a Z ap II rat hippocampus cDNA library (Stratagene, La Jolla, CA) as described previously (Herzog et al., 2001) . Inserts were sequenced and subcloned into the expression vector pcDNA3 (Invitrogen, San Diego, CA).
The neuroendocrine cell line BON (Everest et al., 1991 ) (a kind gift from B. Wiedenmann, Humboldt University, Berlin, Germany) was cultured at 37°C under 5% C O 2 in DM EM/nutrient mix F-12 (1:1) (Invitrogen), supplemented with 7.5% fetal bovine serum, 100 U/ml penicillin, and 100 g /ml streptomycin. After electroporation with the pcDNA3-VGLUT3 plasmid, stable transfectants were selected in the presence of 800 g /ml G418 (Invitrogen), screened by immunofluorescence with a serum against a VGLUT3 peptide (P45-1; see below) and further confirmed using a serum raised to another peptide (P45-3; see below). BON cells stably transfected with rat VGLUT2 or vesicular inhibitory amino acid transporter (VIAAT) cDNAs were used as controls (Herzog et al., 2001) .
Amino acid uptak e assay. For each BON transfectant, cells from four confluent 15 cm dishes (ϳ150 ϫ 10 6 cells) were washed once with PBS, scrapped, and recovered in 10 ml of chilled 0.32 M sucrose and 4 mM H EPES-KOH, pH 7.4. C ells were broken using a Bioneb cell disruption system (Glas-Gol, Terre Haute, I N), with a single cycle of atomization under a 3.3 l /min stream of nitrogen at 2.5 bar. Organelle intactness was assessed by measuring the latency of a lysosomal enzyme, ␤-glucuronidase, using 4-methylumbelliferyl-␤-D-glucuronide as a substrate. T ypically, ϳ60% of ␤-glucuronidase activity was protected in the absence of Triton X-100, showing that an identical percentage of lysosomes remained intact after cell breakage. Nuclei and cell debris were discarded by centrif ugation at 10,000 ϫ g for 5 min. Membranes were then pelleted at 200,000 ϫ g for 20 min and resuspended in 400 l of ice-cold 0.32 M sucrose, 4 mM KC l, 4 mM MgSO 4 , and 10 mM H EPES-KOH, pH 7.4 (uptake buffer).
The transport reaction was started by addition of 10 l of membranes (100 g of protein) to 90 l of uptake buffer containing 2.2 mM ATP, membrane filter (Millipore, Bedford, M A), and three washes with 3 ml of ice-cold 0.15 M KC l. The radioactivity retained on the filters was measured by scintillation counting in Ready Protein ϩ cocktail (Beckman, Fullerton, CA). Each uptake measurement was performed in triplicate and is expressed as mean Ϯ SEM. All experiments were independently performed three or more times on two independent BON-VGLUT3 clones. In each experiment, membranes from VGLUT3-expressing clones were compared with those of VGLUT2 or mock (VIAAT-expressing) transfectants.
RT-PCR . RT-PCR detection of VGLUT3 mRNA in body organs and in different brain areas was performed as described previously (Antunes Bras et al., 1998) with the following primers: 5Ј-ACCCGGGAAGA-ATGGCAGAATC TG-3Ј and 5Ј-ATGGGAAAAGCAATGGGTGTG-GAG-3Ј. RT-PCR generated product with glyceraldehyde-3-phosphate dehydrogenase (G3PDH)-specific probes (C lontech, Palo Alto, CA) was used to normalize the RNA level in tissue sample extracts.
In situ hybridization. Regional in situ hybridization was performed with a mix of six antisense oligonucleotides (5Ј-GTAAGATCCCCAGCGAA-TC TCCCACGGCAT-3Ј, 5Ј-CAATAGGAGAGGCACC TCAGAGCC -C TTAGC -3Ј, 5Ј-AC TCAGC TCAATGGCATC TCCC TCC TCGTT-3Ј, 5Ј-TTCATTC TGGTAGGATAATGGC TCC TCCCC -3Ј, 5Ј-GGATTC -TC TC TGTTGTC TCCGATCCGTC TT-3Ј, and 5Ј-GACC TCACAATT-C TGGGTGGTGGC TCCATA-3Ј) as described previously (Davis et al., 2000; Herzog et al., 2001) . In brief, oligonucleotides were labeled with [
35 S]dATP, using terminal transferase (Amersham Biosciences), to a specific activity of 5 ϫ 10 Ϫ8 dpm /g. Sections were covered with 100 l of a solution containing 50% hybridization solution (Amersham Biosciences), 40% deionized formamide (Merck Eurolab, Strasbourg, France), 500 g /ml poly(A) (Roche, Meylan, France), 100 mM 4-dithiothreitol, and 3-5 ϫ 10 Ϫ5 dpm of each labeled oligonucleotide. The samples were incubated overnight at 42°C, washed, and exposed to x-ray films (Biomax; Eastman Kodak, Rochester, N Y) for 21 d.
The plasmids used to synthesize the cRNA probes for cold in situ hybridization were obtained by PCR amplification with the following primer couples: 5Ј-ACTGTTACCAAGATGCCC-3Ј and 5Ј-ATGAGCA-CGAACCATTCC-3Ј for the rat serotonin transporter (SERT) and 5Ј-AAAACAGGAC TGGGC TGATCC -3Ј and 5Ј-GAGACCAAGATC -CATACGCCC-3Ј for VGLUT3. The choline acetyltransferase (ChAT) plasmid used for cold in situ hybridization was a generous gift from S. Berrard (CNRS UMR7091, Paris, France). Double cold in situ hybridization was performed with antisense riboprobes labeled with either fluorescein-UTP (for ChAT or SERT) or digoxygenin (DIG)-UTP (for VGLUT3) (Herzog et al., 2001) . Colorimetric revelations were obtained with 5-bromo-4-chloro-3-indolyl phosphate (Roche) and either nitroblue tetrazolium (Roche) for VGLUT3 or 2-[4-iodophenyl]-3-[4-nitrophenyl]-5-phenyl-tetrazolium chloride (Roche) for ChAT and SERT, to obtain the blue and red staining, respectively.
Antiserum. T wo anti-VGLUT3 antisera, named P45-1 and P45-3, were obtained by immunizing rabbits (Agro-Bio, Villeny, France) against the following peptides, coupled via their cysteine residues to keyhole limpet hemocyanin: CDSLGIL QRK LDGTN EEGD (Asp 27 -Asp 44 ), and CETEL N H EAFVSPRK K M (Glu 531 -Met 547 ), respectively. Both antisera were decomplemented by heating 30 min at 56°C, dialyzed, and stored in the presence of 50% glycerol at Ϫ20°C. For immunological detection, the antisera were affinity purified on peptides linked to Affigel-15 (Bio-Rad, Richmond, CA).
Immunoautoradiography. Immunoautoradiography was performed as described previously (Herzog et al., 2001) . In brief, adult male Sprague Dawley rats were anesthetized and perf used via the ascending aorta with 200 ml of 0.9% NaC l containing sodium nitrite (1 gm / l). Brains were dissected and frozen in isopentane at Ϫ30°C. Horizontal or coronal rat brain sections were fixed with 4% paraformaldehyde and washed with PBS containing 3% bovine serum albumin (BSA), 1% goat serum, and 1 mM NaI (buffer A). Sections were incubated with buffer supplemented with affinity-purified VGLUT3 antiserum (1:5000 dilution) and then with [
125 I] IgG (0.25 C i /ml; Amersham). Sections were apposed to x-ray films (Biomax; Kodak) for 5 d.
Immunohistochemistr y. Immunocytochemistry was performed as described previously (Herzog et al., 2001) . Adult male Sprague Dawley rats were anesthetized and perf used intracardially with 300 ml of 120 mM sodium phosphate buffer (PB, pH 7.4) supplemented with 4% paraformaldehyde. The brains were dissected, postfixed by immersion in the same fixative, and cryoprotected in PB containing 30% sucrose. Coronal sections were taken at Ϫ20°C and mounted on glass slides. Sections were washed with PB containing gelatin (2 gm / l) and Triton X-100 (0.25%) and incubated with VGLUT3 antiserum in the presence or absence of guinea pig anti-vesicular acetylcholine transporter (VAChT) antiserum (Chemicon, Temecula, CA). VGLUT3 alone was detected with antirabbit IgG coupled to Alexa Fluor 568 dye (Molecular Probes, Eugene, OR). VGLUT3 and VAChT were codetected by immunofluorescence, using goat anti-rabbit IgG coupled to C Y3 and goat anti-guinea-pig coupled to FI TC, respectively, as secondary antibodies. The sections were observed using a conventional (Axioskop 2 Plus; Z eiss, Thornwood, N Y) or a confocal laser scanning (L SM 410; Z eiss) microscope.
VGLUT3 was visualized at the electron-microscopic level using the pre-embedding immunogold method with silver intensification (Bernard et al., 1999) . Briefly, the sections were incubated in goat anti-rabbit IgGs conjugated to gold particles (0.8 nm diameter; 1:100 in PBS/acetylated BSA (BSA-C); Aurion, Wageningen, The Netherlands) for 2 hr in PBS/ BSA-C. The sections were then washed (3ϫ PBS) and postfixed in 1% glutaraldehyde in PBS for 10 min. After washing (2ϫ PBS; 2ϫ sodium acetate buffer, 0.1 M, pH 7.0), the diameter of the gold immunoparticles was increased using a silver enhancement kit (HQ silver; Nanoprobes, Yaphank, N Y) for 5 min at room temperature in the dark. After treatment with 1% osmium, dehydration, and embedding in resin, ultrathin sections were cut, stained with lead citrate, and examined using a Philips (Eindhoven, The Netherlands) C M10 electron microscope or a Philips Tecnai 20. VGLUT3 and VAChT were codetected at the electronmicroscopic level by pre-embedding immunogold and immunoperoxidase, respectively. Briefly, the sections were incubated in a mixture of goat anti-rabbit IgGs conjugated to gold particles (0.8 nm diameter; 1:100 in PBS/ BSA-C; Aurion) and goat anti-guinea pig coupled to biotin (1:200) for 2 hr in PBS/ BSA-C. The sections were then washed (3ϫ PBS) and postfixed in 1% glutaraldehyde in PBS for 10 min. After washing (2ϫ PBS; 2ϫ sodium acetate buffer, 0.1 M, pH 7.0), the diameter of the gold immunoparticles was increased using a silver enhancement kit (HQ silver; Nanoprobes) for 5 min at room temperature in the dark. The sections were finally washed in acetate buffer and in PBS and incubated in an avidin -biotin -peroxidase complex (1:100; Vector Laboratories, Burlingame, CA) for 1.5 hr at room temperature. After washing (2ϫ PBS; 1ϫ Tris buffer, 0.05 M, pH 7.6), the immunoreactive sites for VAChT were revealed using DAB. The sections were treated with 1% osmium, dehydrated, and embedded in resin. Ultrathin sections were cut, stained with lead citrate, and examined in the electron microscope.
RESULTS

Cloning and functional characterization of VGLUT3
A rat hippocampus cDNA library was screened with a combination of VGLUT1 and VGLUT2 probes (Herzog et al., 2001 ). Of 6 ϫ 10 Ϫ5 plated phages, 55 positive clones were isolated and analyzed. Thirty-seven were identical to VGLUT1 and four were identical to VGLUT2. One cDNA, designated P45, encodes a 588 aa protein (calculated M r Ϸ 64,700). P45 is highly homologous to VGLUT1 and VGLUT2 (Ͼ70% aa identity). Most of the divergences between P45, VGLUT1, and VGLUT2 sequences are concentrated in the N and C termini (Fig. 1) .
To analyze whether P45 represents a novel glutamate transporter, its cDNA was stably expressed in the serotoninergic endocrine cell line BON (Evers et al., 1991) . Intracellular membrane vesicles were purified from two independent positive clones (see Fig. 5C ) and analyzed for their capacity to take up [ 3 H]glutamate in the presence of ATP. In each experiment, these vesicles were compared with membranes derived from mock-and VGLUT2-transfected cells. P45-containing vesicles, as VGLUT2-containing membranes, accumulated approximately twice as much [
3 H]glutamate as mock vesicles (Fig. 2 A) . Inhibition of this transport by the H ϩ ionophore CCCP indicated that the increased uptake observed in P45-and VGLUT2-containing membranes was attributable to an H ϩ -driven transport, which was 3.07 Ϯ 0.17 and 4.42 Ϯ 0.28 times higher than in mock vesicles, respectively (means Ϯ SEM; n ϭ 26). For clarity, only the CCCP-sensitive component of uptake is considered hereafter. Because the P45-mediated accumulation of [ 3 H]glutamate remained linear for 15 min (Fig. 3A) , we used a constant duration of 10 min throughout this study.
The bioenergetic properties of P45-and VGLUT2-mediated processes were compared by adding nigericin, an ionophore that collapses transmembrane pH gradients by exchanging H ϩ for K ϩ . As illustrated in Figure 2 B, although nigericin moderately inhibited VGLUT2 by 31.7 Ϯ 2.3%, as reported previously (Bai et al., 2001; Fremeau et al., 2001; Herzog et al., 2001; Varoqui et al., 2002) , a stronger inhibition (70.4 Ϯ 6.1%) was reproducibly observed for P45 (paired t test: p Ͻ 0.001; n ϭ 6). Therefore, the P45-mediated process is more dependent on the chemical component of the H ϩ electrochemical gradient, suggesting that it might translocate more H ϩ than VGLUT2. Both uptakes were abolished by a further addition of valinomycin, a K ϩ ionophore that disrupts the remaining electrical component by exporting the K ϩ ions accumulated by nigericin (Fig. 2 B) . The substrate selectivity of P45 was assessed by applying unlabeled amino acids and/or neurotransmitters simultaneously with [ 3 H]glutamate (Fig. 2C ). L-glutamate (10 mM) inhibited the P45-mediated transport by 92.1 Ϯ 4.1% (n ϭ 6), whereas L-aspartate only partially inhibited uptake (56.5 Ϯ 4.2% inhibition; n ϭ 6). Acetylcholine (n ϭ 5) or GABA (n ϭ 4) at the same concentration (Fig. 2C) or serotonin at 0.5 mM (i.e., approximately two orders of magnitude over its cytosolic concentration in serotoninergic cells) (data not shown) had no effect. The selectivity for L-glutamate over L-aspartate was confirmed by the fact that we could not detect any CCCP-sensitive accumulation of [ 3 H]aspartate induced by P45 (data not shown). Similar results were obtained for VGLUT2 (Fig. 2C) , as reported previously (Bai et al., 2001; Fremeau et al., 2001; Herzog et al., 2001; Takamori et al., 2001; Varoqui et al., 2002) . In contrast, Evans Blue (5 M), a compound that competitively inhibits glutamate uptake into synaptic vesicles (Roseth et al., 1995) , discriminated the P45-and VGLUT2-mediated processes (Fig. 2 D) , because inhibitions of 16.5 Ϯ 5.6 and 55.9 Ϯ 3.4% were observed, respectively (paired t test: p Ͻ 0.005; n ϭ 4). To characterize further the interaction of P45 with glutamate, increasing concentrations of [ 3 H]glutamate were tested. As illustrated in Figure 3C ,D, the P45-mediated uptake followed Michaelis-Menten kinetics, with mean V max and K M values of 20.3 Ϯ 4.8 pmol ⅐ mg Ϫ1 protein ⅐ min Ϫ1 and 0.52 Ϯ 0.21 mM (n ϭ 3). A similar analysis of VGLUT2 kinetics performed in parallel yielded a much higher V max (168 Ϯ 20 pmol ⅐ mg Ϫ1 protein ⅐ min Ϫ1 ) and a slightly higher K M (1.46 Ϯ 0.35 mM) (Fig. 3B,D) . The slower V max of P45, observed with both BON transfectants, may originate from a lower expression of the protein and/or a slower turnover of the transport cycle. To confirm the difference in substrate affinity, additional competition experiments were performed with submillimolar concentrations of unlabeled amino acids (data not shown). Indeed, we found that Figure 5 . Antiserum specificity and regional distribution of VGLUT3. Two polyclonal antisera directed against distinct peptides were generated. A-C, Immunofluorescence detection of VGLUT3 in BON stable transfectants (white puncta) with the P45-1 antiserum at a dilution of 1:5000. The serum recognizes VGLUT3 but not VGLUT1 or VGLUT2 in BON stable transfectants. The same result was obtained with the P45-3 antiserum (data not shown). D-I, Localization of VGLUT3 protein by immunoautoradiography. In D and G-I the P45-3 antiserum was used. In E and F, the P45-1 antiserum was used in the presence ( F) or absence ( E) of its cognate peptide (0.1 mg/ml). Acb, accumbens; CPu, caudate-putamen; DR, dorsal raphe; Ent Cx, entorhinal cortex; Hi, hippocampus; MnR, median raphe nucleus; S, septum; SNC, substantia nigra pars compacta; Tu, olfactory tubercles; VTA, ventral tegmental area. a 0.5 mM concentration of glutamate inhibited P45 more efficiently (by 80.8 Ϯ 3.6%; n ϭ 5) than VGLUT2 (46.9 Ϯ 3.0%). This difference was highly significant (paired t test: p Ͻ 0.005; n ϭ 5). In conclusion, P45 transports glutamate with characteristics very similar, but not identical, to those displayed by VGLUT1 and VGLUT2. Consequently, it was renamed VGLUT3.
Anatomic distribution of VGLUT3
VGLUT3 mRNA distribution in body organs was analyzed by reverse transcription and amplification by PCR (Fig. 4 A) . A 398 kb amplification fragment was found in the brain, eyes, and liver (Fig. 4 A) . In the brain, VGLUT3 was detected in all inspected areas except the cerebellum (Fig. 4 A) .
This finding was confirmed and extended by in situ hybridization analysis, which revealed a very discrete pattern of expression (Fig. 4 B-H ) . No signal is detected in the cerebellum and thalamus. High VGLUT3 mRNA expression is observed in the dorsal and medial raphe nuclei, caudate-putamen, and accumbens (Fig.  4 B,C,E) , whereas low levels are found in the hippocampus (Fig.  4 B,D) and habenula (data not shown). A strong signal was also observed in ependymal cells (Fig. 4 B,D) . At the cellular level, the labeling was concentrated over large, scattered neurons in the striatum (Fig. 4 F) , hippocampus (Fig. 4G) , and cerebral cortex (data not shown). A high density of positive neurons was observed in the dorsal and ventral parts of the raphe dorsalis nucleus (Fig. 4 H) . Lower amounts of VGLUT3 mRNA are also present in the lateral parts of the dorsal raphe (Fig. 4 H) .
Thus, in contrast to VGLUT1 and VGLUT2 (Ni et al., 1994 (Ni et al., , 1995 Hisano et al., 2000; Fremeau et al., 2001; Herzog et al., 2001) , only a few neurons of the brain express VGLUT3.
To examine the localization of the protein, two independent polyclonal antiserums were raised by immunizing rabbits against two different peptides of the VGLUT3 N and C terminus. These two anti-peptide antiserums, named P45-1 and P45-3, gave very similar, if not identical, results in all tested conditions. Both antiserums were able to detect a strong intracellular and punctiform signal on BON cells permanently transfected with pcDNA3-VGLUT3, but not with plasmids coding for VGLUT1 or VGLUT2 (as shown in Fig. 5A -C with P45-3; data not shown for P45-1). On rat brain sections, the same discrete immunoautoradiographic labeling pattern was observed with the two antiserums (Fig. 5D,E) . Finally, the immunolabeling of brain sections was not detected with a preimmune serum (data not shown) or antiserums saturated with their cognate peptides ( Fig. 5F ; data not shown). Together, these experiments demonstrate the specificity of the antiserums.
In contrast to its transcript, the VGLUT3 protein was relatively broadly distributed in the gray matter of the CNS (Fig. 5D-I ) . No signal was detected in the white matter. A strong labeling was observed in the caudate-putamen, accumbens (shell Ͼ core), olfactory tubercles, hippocampus (pyramidal and granular cell layers), ventral tegmental area, substantia nigra (pars compacta), and raphe nuclei (Fig. 5G-I ) . Thus, VGLUT3 mRNA (Fig. 4) and protein (Fig. 5) are present in the same brain regions, but their distribution patterns are not similar. These differences imply that the protein VGLUT3 is not addressed exclusively to cell soma. Furthermore, the regional colocalization of VGLUT3 transcripts and protein suggests that VGLUT3 is expressed by striatal and hippocampal interneurons. However, VGLUT3 is also abundant in regions in which its mRNA is absent, such as the substantia nigra (pars compacta) and ventral tegmental area (Fig. 5H ) . The partial mismatch between the locations of the transcript and the protein suggests that VGLUT3 is also expressed at the terminals of principal neurons.
At the light microscopic level, the caudate-putamen, hippocampus, and raphe nuclei exhibited an intense punctiform labeling of their neuropil (Fig. 6) . VGLUT3 is evenly distributed in the entire striatal neuropil but not in fiber track patches (Fig. 6 A,B) . At higher magnification, this labeling appears as multiple small puncta (Fig. 6 B) . In the hippocampus, VGLUT3-positive neurons, although very scattered (Fig. 4 B,D,G) , produce a dense network surrounding the soma of pyramidal and granular cells (Fig. 6C,D) . VGLUT3 puncta are widespread in the raphe dorsalis (Fig. 6 E,F ) . In the hippocampal formation and raphe nucleus, the puncta have a somewhat larger size than in the striatum (Fig. 6 B,D,F ) .
Localization of VGLUT3 over synaptic vesicle clusters
At the electron-microscopic level, the above-described puncta were found to correspond to nerve endings in the striatum, hippocampus, and raphe nucleus (Fig. 7A-E) , as well as all other inspected brain areas (data not shown). The terminals were identified by the presence of synaptic vesicles. Immunoparticles for VGLUT3 accumulated over vesicle clusters in terminals making classical asymmetrical synapses in the hippocampus (Fig. 7C , arrows) and raphe nucleus (Fig. 7E, arrows) . However, in both structures a large number of VGLUT3-positive terminals are also forming symmetrical synapses (Fig. 7B,D, arrowheads) . The VGLUT3-immunoreactive terminals made close appositions or synaptic contacts with different parts of the neurons. In the CA3 field of the hippocampus, labeled terminals made symmetrical and asymmetrical contacts with dendrites and symmetrical contacts with perikarya of pyramidal neurons. In the dorsal raphe, VGLUT3-positive terminals made symmetrical and asymmetrical synapses with dendrites. In the striatum, VGLUT3 immunolabeled terminals made close appositions and symmetrical contacts with dendrites.
Because this finding does not fit with the conventional view that glutamate synapses make asymmetrical contacts, we investigated the nature of the VGLUT3-positive neurons in more detail.
VGLUT3 is expressed in cholinergic and serotoninergic neurons
The sparse VGLUT3-positive giant cells in the caudate-putamen nucleus are reminiscent of cholinergic neurons, as detected with a probe for the ChAT transcript (Fig. 8 A,C) . We thus compared the expression of the VGLUT3 and ChAT mRNAs, using in situ hybridization with double colorimetric detection. As illustrated in Figure 8 B,D, we found in the caudate-putamen that every ChATpositive neuron (detected by a red precipitate) also expressed VGLUT3 (labeled in blue).
Laser confocal microscopy was then used to investigate the potential colocalization of VGLUT3 with another specific marker of cholinergic nerve endings, the VAChT, at the protein level (Gilmor et al., 1996; Roghani et al., 1996; Weihe et al., 1996) . In the hippocampus (Fig. 8 F) or the septum (data not shown), VGLUT3 (red fluorescence) and VAChT (in green) are clearly present in two distinct sets of nerve terminals. In contrast, in the striatum, numerous thin varicose fibers are labeled in yellow fluorescence, very few are in red, and green terminals are absent (Fig. 8 E) . This experiment suggests that the vast majority of striatal cholinergic terminals contain VGLUT3. Some noncholinergic VGLUT3-positive nerve endings are observed that may originate from brain regions sending projections to the striatum.
In the experiment depicted in Figure 8G , VAChT is detected by immunoperoxidase and VGLUT3 is detected by immunogold at the ultrastructural level. As shown in Figure 8G , two small terminals, containing both the peroxidase precipitate and immunogold particles, are VAChT-as well as VGLUT3-positive, respectively. Thus, the colocalization of VGLUT3 and VAChT in striatal nerve terminals is also confirmed at the electronmicroscopic level.
Together, these results clearly show that almost all cholinergic striatal interneurons express VGLUT3 at their nerve endings.
As shown by in situ hybridization and immunoautoradiography, VGLUT3 is also strongly expressed in the serotoninergic raphe nuclei (Figs. 4 E,H, 9A,B) . We thus analyzed by double in situ hybridization whether VGLUT3 is present in serotoninergic neurons. In Figure 9 , VGLUT3-positive neurons are in blue and serotoninergic neurons, which labeled the plasma membrane SERT transcript, are detected by a red precipitate. As demonstrated by this experiment, all of the SERT-positive neurons also expressed VGLUT3 in the dorsal and median raphe (Fig. 9A,B) . A red/blue neuron is shown at a higher magnification on Figure  9C . Interestingly, numerous neurons from the dorsal raphe are expressing VGLUT3 but not SERT. Accordingly, nonserotoninergic neurons from the raphe dorsalis, which are VGLUT3- Figure 7 . VGLUT3 is localized in nerve endings in the striatum ( A), hippocampus (B, C), and dorsal raphe (D, E) . In all three areas, immunoparticles for VGLUT3 are localized in terminals ( t). In the striatum, dorsal raphe, and hippocampus ( C), the labeled terminals are in close apposition with dendrites ( d). In the hippocampus and dorsal raphe, the immunoreactive terminal makes a symmetrical synapse (arrowheads) with a pyramidal cell (Pyr Cell ) in B and D; one terminal makes an asymmetrical synapse (arrow) with a dendrite ( d) in C and E. Scale bar, 250 nm. positive, could be glutamatergic. Because serotoninergic neurons are known to send projections to the substantia nigra, ventral tegmental area, hippocampus, striatum, and cerebral cortex, the VGLUT3 protein present in these regions might thus originate from the raphe nuclei. However, such an hypothesis needs to be investigated further.
DISCUSSION
VGLUT3 is a novel vesicular glutamate transporter
Two subtypes of vesicular glutamate transporters, named VGLUT1 and VGLUT2, have been characterized recently. In this study we isolated and functionally characterized VGLUT3, a third member of the family. VGLUT3 represents a novel H ϩ -dependent glutamate transporter that is both structurally (75% aa identity) and functionally very similar to VGLUT1 and VGLUT2. Because VGLUT3 localizes to synaptic vesicles, as do VGLUT1 and VGLUT2, we concluded that it is a novel vesicular glutamate transporter. Our study of its uptake activity revealed subtle differences with VGLUT2, including a slightly increased affinity for glutamate, a lesser sensitivity to Evans Blue, and a higher dependence on the ⌬pH component of the proton electrochemical gradient. This last property might represent an intrinsic difference between the two transporters, such as the coupling of the VGLUT3-mediated glutamate uptake to the export of more protons (implying a higher loading of vesicles with glutamate). However, we cannot exclude extrinsic factors, such as the localization of VGLUT2 and VGLUT3 in distinct compartments of the BON cells, differing by their lumenal pH. Additional studies are needed to discriminate between these possibilities. A major (eightfold) difference was also observed for the uptake capacity (V max ) of VGLUT3-and VGLUT2-containing vesicles. However, in the absence of a common ligand enabling us to compare the amounts of both transporters, the issue of whether the slower V max of VGLUT3 reflects a slower turnover or, merely, a lower expression level will remain open.
VGLUT3 has discrete localization
Despite the functional similarity to VGLUT1 and VGLUT2, VGLUT3 differs from these isoforms by several unique anatomical features. First, it is expressed in a few scattered neurons of the brain, in contrast to VGLUT1 and VGLUT2, which are massively expressed throughout large areas of the brain. Neurons expressing VGLUT3 are found in brain regions that also contain the VGLUT1 and VGLUT2 mRNAs, such as the cerebral cortex, hippocampus, and brainstem. However, VGLUT3 is the only vesicular glutamate transporter synthesized by striatal neurons. The regional colocalization of VGLUT3 mRNA and protein, together with the double-labeling experiments, demonstrates that VGLUT3 is expressed by striatal and hippocampal interneurons. Nonetheless, VGLUT3 also seems to be present in neurons from the raphe region sending long projections (for example to the substantia nigra and the ventral tegmental area). Tracing methods as well as lesion studies should help to clarify this point.
VGLUT3 is present in terminals forming symmetrical and asymmetrical synapses
Second, at the ultrastructural level, while VGLUT1 and VGLUT2 are exclusively present in terminals forming asymmetrical synapses (Bellocchio et al., 1998; Fremeau et al., 2001; Fujiyama et al., 2001; Herzog et al., 2001; Sakata-Haga et al., 2001) , VGLUT3 is found in asymmetrical as well as symmetrical synapses. Therefore, if VGLUT3 is fully functional in vivo, the population of excitatory synapses can no longer be identified by a morphological criterion.
It is tantalizing to consider that VGLUT3-positive symmetrical synapses are cholinergic and serotoninergic while asymmetrical synaptic contacts containing VGLUT3 are glutamatergic. According to Fremeau et al. (2001) , all asymmetrical synapses express either VGLUT1 or VGLUT2. It can thus be anticipated that VGLUT3 and VGLUT1 or VGLUT2 are coexpressed in some of these glutamatergic terminals. Such a colocalization is already suspected for VGLUT1 and VGLUT2 (Herzog et al., 2001) .
VGLUT3 is present in cholinergic and serotoninergic neurons
Finally, we report here, for the first time, that cholinergic and serotoninergic neurons express a vesicular glutamate transporter. In this study we have solidly documented the presence VGLUT3 and VAChT in the same terminals. A similar demonstration remains to be established for VGLUT3 and vesicular monoamine transporter type-2 (V M AT2). Whether or not VGLUT3 and VAChT or V M AT2 are found on the same synaptic vesicle is still an open question. If this is the case, then cholinergic and serotoninergic terminals have the potential to store, and thus to release (Takamori et al., 2000 (Takamori et al., , 2001 , glutamate in addition to acetylcholine or serotonin. Indeed, concentrations of glutamate above VGLUT3 K M are achieved in the cytosol of monoaminergic neurons (Kaneko et al., 1990; Danbolt, 2001) . Furthermore, the codetection of the excitatory amino acid on one hand and acetylcholine or serotonin on the other hand in the same terminals has already been reported in other brain areas (C lements and Grant, 1990; Waerhaug and Ottersen, 1993; Lavoie and Parent, 1994a,b; C larke et al., 1996 Lebrand et al., 1996 Lebrand et al., , 1998 C ases et al., 1998; Hökfelt et al., 2000) . The coexpression of the corresponding vesicular transporters thus represents a step f urther. However, the synaptic corelease of glutamate simultaneously with serotonin or acetylcholine, and its physiological relevance, remains to be formally established. Interestingly, a recent study has reported that dopaminergic neurons can also form asymmetric synaptic specialization and release glutamate in vitro (Sulzer et al., 1998) . This study supports the working hypothesis that the corelease of glutamate with other transmitters may be more general than currently suspected.
However, it cannot be ruled out that VGLUT3 is addressed to a different set of functional synaptic vesicles than VAChT/ VMAT2. Alternatively, VGLUT3 could be present in vesicles that do not belong to a readily releasable pool or are in the reserve pool. Moreover, to our knowledge, the presence of glutamate receptor in postsynaptic specialization of the synaptic cleft of cholinergic or serotoninergic neurons has not been documented. If VGLUT3 is in the reserve pool of vesicles or if glutamate ion channel receptors are not present, the physiological function of VGLUT3 will have to be elucidated. Consequently the main challenge for the forthcoming studies on VGLUT3 will be to clearly establish its functionality in monoaminergic neurons.
Cholinergic and serotoninergic neurons are involved in a wide variety of neurological and psychiatric diseases (Kawaguchi et al., 1995; Calabresi et al., 1997; Pollack, 2001) . Because of its discrete localization in these neurons, VGLUT3 represents a promising therapeutic target for these pathologies.
